Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Keryn G. Woodman"'
Autor:
Justin Cohen, Shushu Huang, Katherine E. Koczwara, Kristen T. Woods, Vincent Ho, Keryn G. Woodman, Jack L. Arbiser, Katelyn Daman, Monkol Lek, Charles P. Emerson, Alec M. DeSimone
Publikováno v:
Cell Death and Disease, Vol 14, Iss 11, Pp 1-12 (2023)
Abstract Facioscapulohumeral muscular dystrophy (FSHD) is among the most common of the muscular dystrophies, affecting nearly 1 in 8000 individuals, and is a cause of profound disability. Genetically, FSHD is linked to the contraction and/or epigenet
Externí odkaz:
https://doaj.org/article/cfe51ae4c4fd43efbd0f592112c8ab39
Publikováno v:
Molecules, Vol 26, Iss 4, p 853 (2021)
Duchenne muscular dystrophy (DMD) is a progressive fatal neuromuscular disorder with no cure. Therapies to restore dystrophin deficiency have been approved in some jurisdictions but long-term effectiveness is yet to be established. There is a need to
Externí odkaz:
https://doaj.org/article/3fb2f6286a064f529df35e17f048ded3
Publikováno v:
Nutrients, Vol 8, Iss 11, p 713 (2016)
In recent years, complementary and alternative medicine has become increasingly popular. This trend has not escaped the Duchenne Muscular Dystrophy community with one study showing that 80% of caregivers have provided their Duchenne patients with com
Externí odkaz:
https://doaj.org/article/08938126eb8542959c5ffe074fa8b9be
Publikováno v:
Human Gene Therapy. 32:260-274
Clustered regularly interspaced short palindromic repeat (CRISPR)-based technology has been adapted to achieve a wide range of genome modifications, including transcription regulation. The focus of...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95294f77885a4cbae110cf5cff29d20b
https://doi.org/10.1089/hum.2020.241
https://doi.org/10.1089/hum.2020.241
Publikováno v:
Human gene therapy. 32(5-6)
Clustered regularly interspaced short palindromic repeat (CRISPR)-based technology has been adapted to achieve a wide range of genome modifications, including transcription regulation. The focus of this review is on the application of CRISPR-based pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5a7ceb049f5f1e4a4c9a2cadb8dfffcd
https://pubmed.ncbi.nlm.nih.gov/33446040
https://pubmed.ncbi.nlm.nih.gov/33446040
Publikováno v:
Molecules
Volume 26
Issue 4
Molecules, Vol 26, Iss 853, p 853 (2021)
Volume 26
Issue 4
Molecules, Vol 26, Iss 853, p 853 (2021)
Duchenne muscular dystrophy (DMD) is a progressive fatal neuromuscular disorder with no cure. Therapies to restore dystrophin deficiency have been approved in some jurisdictions but long-term effectiveness is yet to be established. There is a need to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2da188a20316c44058b23e4889eac1b2
https://pubmed.ncbi.nlm.nih.gov/33561994
https://pubmed.ncbi.nlm.nih.gov/33561994
Autor:
James Conner, Oliver D. King, Angela Lek, Monkol Lek, Lillian Mead, Kathryn R. Wagner, Keryn G. Woodman, Vincent T. Ho, Neville E. Sanjana, Justin B. Cohen, Shushu Huang, Louis M. Kunkel, Peter L. Jones, Anna Pakula, Yuanfan Zhang, Andrew Kodani, Alec M. DeSimone
Publikováno v:
Sci Transl Med
The emergence of CRISPR-Cas9 gene-editing technologies and genome-wide CRISPR-Cas9 libraries enables efficient unbiased genetic screening that can accelerate the process of therapeutic discovery for genetic disorders. Here, we demonstrate the utility
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e95707ef4e2ef15d8ed9c5251b18b7b
https://europepmc.org/articles/PMC7304480/
https://europepmc.org/articles/PMC7304480/
Autor:
Christopher Kintakas, Adam T. Piers, Keryn G. Woodman, Tracie Webster, Chantal A. Coles, Su L Touslon, Gayle M. Smythe, Lavinia Gordon, Shireen R. Lamandé, Liam C. Hunt, Jason D. White
Publikováno v:
Human molecular genetics. 29(3)
Duchenne muscular dystrophy (DMD) is a lethal muscle wasting disorder caused by mutations in the DMD gene that lead to the absence or severe reduction of dystrophin protein in muscle. The mdx mouse, also dystrophin deficient, is the model most widely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::486837a40bfe89341c43592eb3224770
https://pubmed.ncbi.nlm.nih.gov/31696230
https://pubmed.ncbi.nlm.nih.gov/31696230
Autor:
Knight M, McDonagh M, Shireen R. Lamandé, Toulson Sl, Keryn G. Woodman, Chantal A. Coles, Jonathan M. White
Duchenne muscular dystrophy (DMD) is a progressive and fatal neuromuscular disorder for which there is no treatment. Therapies to restore dystrophin deficiency are not ready for clinical use and long-term efficiency is yet to be established. Therefor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0ca933cd8435164e3cefb1b00c22612
https://doi.org/10.1101/289587
https://doi.org/10.1101/289587
Autor:
Rachelle H. Crosbie-Watson, Lamandé, Keryn G. Woodman, Elizabeth M. Gibbs, Jason D. White, McDonagh M, Chantal A. Coles, Toulson Sl, Knight M
Duchenne Muscular Dystrophy (DMD) is a progressive and fatal neuromuscular disease which arises from mutations in the dystrophin gene (DMD) that result in the absence or severe reduction of the cytoskeletal protein dystrophin. In addition to the prim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0744b91f3626949f963b981013b7026e
https://doi.org/10.1101/288621
https://doi.org/10.1101/288621